AskBio’s gene therapy shows promising 12-month results for heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Subscribe To Our Newsletter & Stay Updated